<DOC>
	<DOCNO>NCT01174368</DOCNO>
	<brief_summary>This clinical research study investigational ( FDA IND-BB 10091 ) treatment subject castration-resistant prostate cancer resistant Taxanes ( docetaxel , cabazitaxel ) evidence disease progression androgen-axis inhibition and/or immunotherapy form sipuleucel-T . The treatment evaluate effect tumor growth . It consist placement ( implantation ) small bead contain mouse renal adenocarcinoma cell ( RENCA macrobeads ) . The cell macrobeads produce substance show slow stop growth tumor experimental animal veterinary patient . It test 31 human subject different type cancer Phase I safety trial . Phase II study patient colorectal , pancreatic prostate cancer progress .</brief_summary>
	<brief_title>Efficacy Trial Implantation Mouse Renal Adenocarcinoma Macrobeads Subjects With Castration-Resistant Prostate Cancer Resistant Taxanes ( Docetaxel , Cabazitaxel ) Evidence Disease Progression Androgen-axis Inhibition and/or Immunotherapy Form Sipuleucel-T</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Cancer prostate Evidence metastasis Failed available therapy Resolution toxic effect previous therapy Performance status ( ECOG PS ) 02 Adequate hematologic , coagulation ( INR 23max ) , hepatic renal function Life expectancy 12 month Agrees contraceptive use study sexually active Sign inform consent document Any condition presenting unacceptably high anesthetic surgical risk HIV positive Cognitive impairment preclude inform consent Other surgical treatment , chemotherapy radiation within four week baseline Inadequate hematologic , coagulation ( INR &gt; 3 ) , hepatic , renal function Hepatic blood flow abnormality and/or largevolume ascites Concurrent cancer type except skin cancer ( exclude melanoma ) History allergic reaction mouse antigen Active infection , congestive heart failure , unstable angina , serious cardiac arrhythmia , psychiatric illness , difficult social situation permit reliable participation , active bleeding</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>